Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving biomarkers. The trials were global, involved ...
(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results